cantharidin has been researched along with Condylomata Acuminata in 4 studies
Cantharidin: A toxic compound, isolated from the Spanish fly or blistering beetle (Lytta (Cantharis) vesicatoria) and other insects. It is a potent and specific inhibitor of protein phosphatases 1 (PP1) and 2A (PP2A). This compound can produce severe skin inflammation, and is extremely toxic if ingested orally.
cantharidin : A monoterpenoid with an epoxy-bridged cyclic dicarboxylic anhydride structure secreted by many species of blister beetle, and most notably by the Spanish fly, Lytta vesicatoria. Natural toxin inhibitor of protein phosphatases 1 and 2A.
Condylomata Acuminata: Sexually transmitted form of anogenital warty growth caused by the human papillomaviruses.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Adverse events experienced by the VP-102-treated participants were consistent with the pharmacodynamic action of cantharidin as a vesicant and were primarily mild to moderate in severity." | 7.01 | Phase II, Double-Blind, Vehicle-Controlled Study to Determine the Cantharidin Dose Regimen, Efficacy, Safety, and Tolerability of VP-102 in Subjects with External Genital Warts. ( Andres, J; Eads, K; Glover, DK; Guenthner, S; McFalda, W; Olivadoti, M; Rieger, J; Rosen, T; Rumney, P; Tate, M; Willson, C, 2021) |
| " Adverse events experienced by the VP-102-treated participants were consistent with the pharmacodynamic action of cantharidin as a vesicant and were primarily mild to moderate in severity." | 3.01 | Phase II, Double-Blind, Vehicle-Controlled Study to Determine the Cantharidin Dose Regimen, Efficacy, Safety, and Tolerability of VP-102 in Subjects with External Genital Warts. ( Andres, J; Eads, K; Glover, DK; Guenthner, S; McFalda, W; Olivadoti, M; Rieger, J; Rosen, T; Rumney, P; Tate, M; Willson, C, 2021) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (25.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (25.00) | 24.3611 |
| 2020's | 2 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Guenthner, S | 1 |
| McFalda, W | 1 |
| Tate, M | 1 |
| Eads, K | 1 |
| Rieger, J | 1 |
| Glover, DK | 1 |
| Willson, C | 1 |
| Rumney, P | 1 |
| Rosen, T | 1 |
| Andres, J | 1 |
| Olivadoti, M | 1 |
| Ruini, C | 1 |
| Clanner-Engelshofen, BM | 1 |
| Heppt, M | 1 |
| Herzinger, T | 1 |
| Sárdy, M | 1 |
| Ruzicka, T | 1 |
| French, LE | 1 |
| Reinholz, M | 1 |
| Recanati, MA | 1 |
| Kramer, KJ | 1 |
| Maggio, JJ | 1 |
| Chao, CR | 1 |
| Coskey, RJ | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Phase 2, Double-Blind, Placebo-Controlled Study to Determine the Dose Regimen, Efficacy, Safety, and Tolerability of VP-102 in Subjects With External Genital Warts[NCT03981822] | Phase 2 | 105 participants (Actual) | Interventional | 2019-06-25 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
"Change from baseline in the number of treatable warts (baseline and new) at Treatment Visit 2, Treatment Visit 3, Treatment Visit 4, Study Day 84 (EOT), and Follow-up Visits on Study Day 112 and Study Day 147 (EOS).~Number of warts present were recorded at each treatment visit as well as follow-up visits. For each post baseline treatment visit, the change in number of warts from baseline was calculated." (NCT03981822)
Timeframe: Compared from baseline to each study visit, treatment 2 (Day 21), 3 (Day 42), 4 (Day 63) and Day 84, 112 and 147.
| Intervention | Warts (Mean) | |||||
|---|---|---|---|---|---|---|
| Treatment Visit 2 | Treatment Visit 3 | Treatment Visit 4 | Study Day 84 EOT Visit | Follow up Day 112 | Follow-up Visit Day 147 EOS | |
| Part B Pooled With Part A VP-102 24-hour | -5.3 | -6.3 | -7.1 | -7.4 | -8.1 | -7.9 |
| Part B Pooled With Part A: Placebo 24-hour | 0.6 | -0.5 | 0.5 | 0.1 | -0.3 | -0.1 |
| Part B Pooled With Part A: Placebo 6-hour | -0.3 | -1.1 | -0.9 | -1.1 | -1.1 | -1.2 |
| Part B Pooled With Part A: VP-102 6-hour | -4.0 | -4.4 | -5.2 | -6.1 | -5.3 | -5.0 |
Change from baseline in total wart area (sum of individual warts) at Study Day 84 (EOT), and Follow-up Visits on Study Day 112 and Study Day 147 (EOS). (NCT03981822)
Timeframe: Baseline to Study Day 84, Follow-up Visits at Days 112 and 147 (EOS)
| Intervention | mm^2 (Mean) | ||
|---|---|---|---|
| Study Day 84 (EOT) | Follow-up Day 112 | Follow-up Visit Day 147 (EOS) | |
| Part B Pooled With Part A VP-102 24-hour | -72.87 | -82.79 | -68.78 |
| Part B Pooled With Part A: Placebo 24-hour | 1.60 | 1.40 | 2.21 |
| Part B Pooled With Part A: Placebo 6-hour | -23.64 | -20.35 | -6.02 |
| Part B Pooled With Part A: VP-102 6-hour | -52.60 | -79.43 | -59.28 |
Percent Change from Baseline in the Number of Treatable Warts (Baseline and New) at Treatment Visit 2, Treatment Visit 3, Treatment Visit 4, at Study Day 84 (EOT), and Follow-up Visits on Study Day 112 and Study Day 147 (EOS). (NCT03981822)
Timeframe: Percent change from baseline to each study visit, treatment 2 (Day 21), 3 (Day 42), 4 (Day 63) and Day 84, 112 and 147.
| Intervention | Wart percentage change from Baseline (Mean) | |||||
|---|---|---|---|---|---|---|
| Treatment Visit 2 | Treatment Visit 3 | Treatment Visit 4 | Study Day 84 End of Treatment Visit | Follow up Day 112 | Follow up Visit Day 147 End of Study | |
| Part B Pooled With Part A VP-102 24-hour | -58.5 | -69.3 | -77.3 | -77.1 | -79.2 | -79.6 |
| Part B Pooled With Part A: Placebo 24-hour | -2.6 | -17.8 | 0.6 | -5.5 | -14.2 | -12.9 |
| Part B Pooled With Part A: Placebo 6-hour | -6.2 | -8.9 | -5.1 | -1.6 | 1.9 | -6.0 |
| Part B Pooled With Part A: VP-102 6-hour | -41.4 | -49.0 | -65.8 | -79.7 | -68.2 | -42.5 |
Percent Change from baseline in the total wart area (sum of individual warts) at Study Day 84 (EOT), and Follow-up Visits on Study Day 112 and Study Day 147 (EOS). (NCT03981822)
Timeframe: Baseline to Study Day 84 (EOT), and Follow-up Visits on Study Day 112 and Study Day 147 (EOS)
| Intervention | Change from baseline in % of wart area (Mean) | ||
|---|---|---|---|
| Study Day 84 (EOT) | Follow-up Day 112 | Follow-up Day 147 (EOS) | |
| Part B Pooled With Part A VP-102 24-hour | -64.2 | -76.4 | -69.3 |
| Part B Pooled With Part A: Placebo 24-hour | -7.3 | 13.8 | 19.9 |
| Part B Pooled With Part A: Placebo 6-hour | -22.3 | -21.5 | -11.7 |
| Part B Pooled With Part A: VP-102 6-hour | -46.0 | -48.2 | -45.8 |
Proportion of subjects exhibiting 75% clearance of all treatable warts (baseline and new) at Treatment Visit 2, Treatment Visit 3, Treatment Visit 4, Study Day 84 (EOT), and Follow-up Visits on Study Day 112 and Study Day 147 (EOS). (NCT03981822)
Timeframe: Compared from baseline to each study visit, treatment 2, (Day 21), 3 (Day 42), 4 (Day 63) and Day 84, 112 and 147.
| Intervention | Participants (Count of Participants) | |||||
|---|---|---|---|---|---|---|
| Treatment Visit 2: Incidence of >=75% Clearance: YES | Treatment Visit 3: Incidence of >=75% Clearance: YES | Treatment Visit 4: Incidence of >=75% Clearance: YES | Study Day 84 EOT: Incidence of >=75% Clearance: YES | F/U Visit Day 112: Incidence of >=75% Clearance: YES | F/U Visit Day 147: Incidence of >=75% Clearance: YES | |
| Part B Pooled With Part A VP-102 24-hour | 6 | 14 | 12 | 15 | 13 | 13 |
| Part B Pooled With Part A: Placebo 24-hour | 1 | 2 | 1 | 2 | 3 | 2 |
| Part B Pooled With Part A: Placebo 6-hour | 0 | 0 | 2 | 2 | 3 | 4 |
| Part B Pooled With Part A: VP-102 6-hour | 5 | 8 | 11 | 15 | 13 | 10 |
Proportion of subjects exhibiting 90% clearance of all treatable warts (baseline and new) at Treatment Visit 2, Treatment Visit 3, Treatment Visit 4, Study Day 84 (EOT), and Follow-up Visits on Study Day 112 and Study Day 147 (EOS). (NCT03981822)
Timeframe: Compared from baseline to each study visit, treatment 2 (Day 21), 3 (Day 42), 4 (Day 63) and Day 84, 112 and 147.
| Intervention | Participants (Count of Participants) | |||||
|---|---|---|---|---|---|---|
| Treatment Visit 2: Incidence of >=90% Clearance: YES | Treatment Visit 3: Incidence of >=90% Clearance: YES | Treatment Visit 4: Incidence of >=90% Clearance: YES | Study Day 84 EOT: Incidence of >=90% Clearance: YES | F/U Visit Day 112: Incidence of >=90% Clearance: YES | F/U Visit Day 147: Incidence of >=90% Clearance: YES | |
| Part B Pooled With Part A VP-102 24-hour | 4 | 8 | 7 | 11 | 9 | 9 |
| Part B Pooled With Part A: Placebo 24-hour | 0 | 2 | 0 | 0 | 2 | 2 |
| Part B Pooled With Part A: Placebo 6-hour | 0 | 0 | 0 | 2 | 2 | 3 |
| Part B Pooled With Part A: VP-102 6-hour | 1 | 5 | 7 | 14 | 11 | 9 |
Proportion of subjects exhibiting complete clearance of all treatable warts (baseline and new) at Treatment Visit 2, Treatment Visit 3, Treatment Visit 4, and Follow-up Visits on Study Day 112 and Study Day 147 (EOS). (NCT03981822)
Timeframe: Clearance compared from baseline to each study visit, treatment 2 (Day 21), 3 (Day 42), 4 (Day 63) and Day 84, 112 and 147.
| Intervention | Participants (Count of Participants) | |||||
|---|---|---|---|---|---|---|
| Treatment Visit 2: Yes, Complete Clearance | Treatment Visit 3: Yes, Complete Clearance | Treatment Visit 4: Yes, Complete Clearance | Study Day 84 EOT: Yes, Complete Clearance | F/U Visit Day 112: Yes, Complete Clearance | F/U Visit Day 147: Yes, Complete Clearance | |
| Part B Pooled With Part A VP-102 24-hour | 4 | 8 | 7 | 9 | 8 | 8 |
| Part B Pooled With Part A: Placebo 24-hour | 0 | 2 | 0 | 0 | 2 | 2 |
| Part B Pooled With Part A: Placebo 6-hour | 0 | 0 | 0 | 1 | 2 | 3 |
| Part B Pooled With Part A: VP-102 6-hour | 1 | 4 | 6 | 11 | 9 | 6 |
Proportion of subjects exhibiting reduction of ≥ 1 treatable wart from baseline at Treatment Visit 2, Treatment Visit 3, Treatment Visit 4, Study Day 84 (EOT), and Follow-up Visits on Study Day 112 and Study Day 147 (EOS). (NCT03981822)
Timeframe: Compared from baseline to each study visit, treatment 2 (Day 21), 3 (Day 42), 4 (Day 63) and Day 84, 112 and 147.
| Intervention | Participants (Count of Participants) | |||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Treatment Visit 272493885 | Treatment Visit 272493886 | Treatment Visit 272493884 | Treatment Visit 272493887 | Treatment Visit 372493884 | Treatment Visit 372493885 | Treatment Visit 372493886 | Treatment Visit 372493887 | Treatment Visit 472493884 | Treatment Visit 472493885 | Treatment Visit 472493886 | Treatment Visit 472493887 | Study Day 84 EOT Visit72493884 | Study Day 84 EOT Visit72493885 | Study Day 84 EOT Visit72493886 | Study Day 84 EOT Visit72493887 | F/U Visit Day 11272493884 | F/U Visit Day 11272493885 | F/U Visit Day 11272493886 | F/U Visit Day 11272493887 | F/U Visit Day 147 EOS72493884 | F/U Visit Day 147 EOS72493885 | F/U Visit Day 147 EOS72493886 | F/U Visit Day 147 EOS72493887 | |||||||||||||||||||||||||
| No | Yes - at least 1 wart reduction from Baseline | |||||||||||||||||||||||||||||||||||||||||||||||
| Part B Pooled With Part A: VP-102 6-hour | 22 | |||||||||||||||||||||||||||||||||||||||||||||||
| Part B Pooled With Part A: Placebo 6-hour | 6 | |||||||||||||||||||||||||||||||||||||||||||||||
| Part B Pooled With Part A VP-102 24-hour | 23 | |||||||||||||||||||||||||||||||||||||||||||||||
| Part B Pooled With Part A: Placebo 24-hour | 6 | |||||||||||||||||||||||||||||||||||||||||||||||
| Part B Pooled With Part A: VP-102 6-hour | 8 | |||||||||||||||||||||||||||||||||||||||||||||||
| Part B Pooled With Part A: Placebo 6-hour | 18 | |||||||||||||||||||||||||||||||||||||||||||||||
| Part B Pooled With Part A VP-102 24-hour | 4 | |||||||||||||||||||||||||||||||||||||||||||||||
| Part B Pooled With Part A: Placebo 24-hour | 12 | |||||||||||||||||||||||||||||||||||||||||||||||
| Part B Pooled With Part A: VP-102 6-hour | 20 | |||||||||||||||||||||||||||||||||||||||||||||||
| Part B Pooled With Part A VP-102 24-hour | 21 | |||||||||||||||||||||||||||||||||||||||||||||||
| Part B Pooled With Part A: Placebo 24-hour | 7 | |||||||||||||||||||||||||||||||||||||||||||||||
| Part B Pooled With Part A: VP-102 6-hour | 10 | |||||||||||||||||||||||||||||||||||||||||||||||
| Part B Pooled With Part A VP-102 24-hour | 6 | |||||||||||||||||||||||||||||||||||||||||||||||
| Part B Pooled With Part A: Placebo 24-hour | 11 | |||||||||||||||||||||||||||||||||||||||||||||||
| Part B Pooled With Part A: VP-102 6-hour | 23 | |||||||||||||||||||||||||||||||||||||||||||||||
| Part B Pooled With Part A VP-102 24-hour | 17 | |||||||||||||||||||||||||||||||||||||||||||||||
| Part B Pooled With Part A: Placebo 24-hour | 4 | |||||||||||||||||||||||||||||||||||||||||||||||
| Part B Pooled With Part A: VP-102 6-hour | 7 | |||||||||||||||||||||||||||||||||||||||||||||||
| Part B Pooled With Part A VP-102 24-hour | 10 | |||||||||||||||||||||||||||||||||||||||||||||||
| Part B Pooled With Part A: Placebo 24-hour | 14 | |||||||||||||||||||||||||||||||||||||||||||||||
| Part B Pooled With Part A: VP-102 6-hour | 19 | |||||||||||||||||||||||||||||||||||||||||||||||
| Part B Pooled With Part A: Placebo 6-hour | 9 | |||||||||||||||||||||||||||||||||||||||||||||||
| Part B Pooled With Part A: VP-102 6-hour | 11 | |||||||||||||||||||||||||||||||||||||||||||||||
| Part B Pooled With Part A: Placebo 6-hour | 15 | |||||||||||||||||||||||||||||||||||||||||||||||
| Part B Pooled With Part A VP-102 24-hour | 9 | |||||||||||||||||||||||||||||||||||||||||||||||
| Part B Pooled With Part A: Placebo 6-hour | 10 | |||||||||||||||||||||||||||||||||||||||||||||||
| Part B Pooled With Part A VP-102 24-hour | 18 | |||||||||||||||||||||||||||||||||||||||||||||||
| Part B Pooled With Part A: Placebo 6-hour | 14 | |||||||||||||||||||||||||||||||||||||||||||||||
| Part B Pooled With Part A: VP-102 6-hour | 13 | |||||||||||||||||||||||||||||||||||||||||||||||
| Part B Pooled With Part A: Placebo 6-hour | 8 | |||||||||||||||||||||||||||||||||||||||||||||||
| Part B Pooled With Part A VP-102 24-hour | 19 | |||||||||||||||||||||||||||||||||||||||||||||||
| Part B Pooled With Part A: Placebo 24-hour | 5 | |||||||||||||||||||||||||||||||||||||||||||||||
| Part B Pooled With Part A: VP-102 6-hour | 17 | |||||||||||||||||||||||||||||||||||||||||||||||
| Part B Pooled With Part A: Placebo 6-hour | 16 | |||||||||||||||||||||||||||||||||||||||||||||||
| Part B Pooled With Part A VP-102 24-hour | 8 | |||||||||||||||||||||||||||||||||||||||||||||||
| Part B Pooled With Part A: Placebo 24-hour | 13 | |||||||||||||||||||||||||||||||||||||||||||||||
1 review available for cantharidin and Condylomata Acuminata
| Article | Year |
|---|---|
What's new about warts.
Topics: Antibodies, Viral; Cantharidin; Child; Condylomata Acuminata; Dinitrochlorobenzene; Glutaral; Humans | 1976 |
2 trials available for cantharidin and Condylomata Acuminata
| Article | Year |
|---|---|
Phase II, Double-Blind, Vehicle-Controlled Study to Determine the Cantharidin Dose Regimen, Efficacy, Safety, and Tolerability of VP-102 in Subjects with External Genital Warts.
Topics: Administration, Cutaneous; Adult; Cantharidin; Condylomata Acuminata; Double-Blind Method; Drug Admi | 2021 |
Cantharidin is Superior to Trichloroacetic Acid for the Treatment of Non-mucosal Genital Warts: A Pilot Randomized Controlled Trial.
Topics: Adult; Cantharidin; Condylomata Acuminata; Female; Humans; Irritants; Male; Papillomaviridae; Pilot | 2018 |
1 other study available for cantharidin and Condylomata Acuminata
| Article | Year |
|---|---|
Cantharidin as an Alternative Treatment for Genital Warts: A Case Monitored With Optical Coherence Tomography.
Topics: Cantharidin; Condylomata Acuminata; Humans; Papillomaviridae; Tomography, Optical Coherence; Warts | 2020 |